Market Research Report
Epiomic Epidemiology Series: Congenital Adrenal Hyperplasia Forecast in 31 Major Markets 2018-2028
|Published by||Black Swan Analysis||Product code||701127|
|Published||Content info||84 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Congenital Adrenal Hyperplasia Forecast in 31 Major Markets 2018-2028|
|Published: September 1, 2018||Content info: 84 Pages||
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Congenital Adrenal Hyperplasia in 31 Major Markets
Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids. This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics. CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity. This report covers only the classic form of the disorder.
This report provides the current prevalent population for CAH across 31 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Czech Republic, Hungary, Romania, Croatia, Russia, Turkey, Egypt, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, CAH patients grouped by disease form have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Ability to quantify patient populations in global CAH market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of CAH and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Identification of CAH patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of CAH patients.